Dual CRISPR-Cas3 system for inducing multi-exon skipping in DMD patient-derived iPSCs

Stem Cell Reports. 2023 Sep 12;18(9):1753-1765. doi: 10.1016/j.stemcr.2023.07.007. Epub 2023 Aug 24.

Abstract

To restore dystrophin protein in various mutation patterns of Duchenne muscular dystrophy (DMD), the multi-exon skipping (MES) approach has been investigated. However, only limited techniques are available to induce a large deletion to cover the target exons spread over several hundred kilobases. Here, we utilized the CRISPR-Cas3 system for MES induction and showed that dual crRNAs could induce a large deletion at the dystrophin exon 45-55 region (∼340 kb), which can be applied to various types of DMD patients. We developed a two-color SSA-based reporter system for Cas3 to enrich the genome-edited cell population and demonstrated that MES induction restored dystrophin protein in DMD-iPSCs with three distinct mutations. Whole-genome sequencing and distance analysis detected no significant off-target deletion near the putative crRNA binding sites. Altogether, dual CRISPR-Cas3 is a promising tool to induce a gigantic genomic deletion and restore dystrophin protein via MES induction.

Keywords: CRISPR-Cas3; DMD; exon skipping; gene therapy; genome editing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Binding Sites
  • CRISPR-Cas Systems / genetics
  • Dystrophin* / genetics
  • Exons / genetics
  • Humans
  • Muscular Dystrophy, Duchenne* / genetics
  • Muscular Dystrophy, Duchenne* / therapy

Substances

  • Dystrophin